Volume Alert - GILD 102.05 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - GILD 102.05 Gilead Sciences $GILD Hit a high today of 102.42 Closing the day 10:30 at 102.05 +1.61 +1.60% With a day low of 100.82 and a total volume of 5,075,960.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Gilead Sciences (GILD) Stock Rises After European Commission Market Authorization for Harvoni
at The Street - 32 mins ago
Shares of Gilead Sciences (GILD) were up in morning trading Tuesday after the European Commission granted marketing authorization for its hepatitis C treatment Harvoni.
GILD: 102.05 (+1.61)

Early Glance: Biotechnology companies
AP - 57 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 102.04 (+1.60), AMGN: 160.54 (+1.40), CELG: 106.47 (+2.11)

Harvoni cleared in Europe
Seeking Alpha - at Seeking Alpha - 1 hr 5 mins ago

GILD: 102.04 (+1.60)

European Commission Grants Marketing Authorization for Gilead's Harvoni(R) (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4
Business Wire - 1 hr 13 mins ago
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the European Commission has granted marketing authorization for Harvoni(R) (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir (LDV) with the nucleotide analog polymerase inhibitor sofosbuvir (SOF), approved by the European Commission under the tradename Sovaldi(R) in January 2014.
GILD: 102.04 (+1.60)

Next Resistance Level for Gilead Sciences (GILD) is $102.81
Comtex SmarTrend(R) - 1 hr 21 mins ago
Shares of Gilead Sciences (NASDAQ:GILD) opened today above their pivot of $100.95 and have already reached the first level of resistance at $101.60. Should the shares continue to rise, the resistance pivots of $102.81 and $104.67 will be of interest.
GILD: 102.04 (+1.60)

Buy Gilead Sciences Now At A Historic Low Valuation
Ken McGaha - at Seeking Alpha - 2 hrs 28 mins ago

GILD: 102.04 (+1.60)

Earnings Forecast Buzz for Baker Hughes, Halliburton, Apple, Gilead Sciences, Kinder Morgan, and Alibaba
PR Newswire - 2 hrs 35 mins ago
EarningForecast.com has issued earnings forecast research with special focus on financial performance of the following stocks: Baker Hughes (NYSE:BHI), Halliburton (NYSE:HAL), Apple (NASDAQ:AAPL), Gilead Sciences (NASDAQ:GILD), Kinder Morgan (NYSE:KMI), and Alibaba (NYSE:BABA).
KMI: 40.56 (+0.31), GILD: 102.04 (+1.60), HAL: 49.55 (+0.32), AAPL: 114.34 (+0.35), BABA: 111.87 (-2.38), BHI: 65.71 (+0.48)

Dispelling Some Of The Myths Surrounding Gilead Sciences.
Alexander J. Poulos - Seeking Alpha - 2 hrs 57 mins ago
Gilead Sciences (NASDAQ: GILD ) has come under fire recently, as many are fretting about the long-term viability of the company's hepatitis C franchise (HCV). The article below will build the case for the superiority of the GILD treatment as opposed...
GILD: 102.04 (+1.60), ABBV: 65.69 (+0.65)

Final Glance: Biotechnology companies
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 102.04 (+1.60), AMGN: 160.53 (+1.39), CELG: 106.47 (+2.11)

Gilead Sciences Earnings Hindsight: Down 10.0% in Last 20 Days (GILD)
Comtex SmarTrend(R) - Mon Nov 17, 3:00PM CST
When Gilead Sciences (NASDAQ:GILD) reported earnings 20 days ago on October 28th, 2014, analysts, on average, expected the company to report earnings of $1.93 on sales of $6.0 billion. The company actually reported EPS of $1.84 on sales of $6.0 billion, missing EPS estimates by $0.09 and beating revenue estimates by $5.4 million. Since the company's report, shares of Gilead Sciences have fallen from $113.45 to $102.06, representing a loss of 10.0% in the past 20 days.
GILD: 102.04 (+1.60)

Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 109.00 (+0.70), GILD: 102.04 (+1.60), GERN: 3.11 (+0.13), MRK: 59.79 (+0.33), AZN: 73.38 (+0.88), PFE: 30.55 (+0.23), INCY: 70.08 (+0.38), BMY: 58.76 (+0.33), CTIC: 2.27 (+0.03), NVS: 95.38 (+1.00)

Jim Cramer Answers Twitter (TWTR) Questions on Gold, Gilead and More
at The Street - Mon Nov 17, 1:53PM CST
TheStreet's Jim Cramer answers Twitter (TWTR) questions on gold, Gilead (GILD), energy stocks and more.
JNJ: 109.00 (+0.70), GILD: 102.04 (+1.60), GLD: 114.96 (+0.91), ABBV: 65.69 (+0.65), TWTR: 40.58 (+0.11), NVS: 95.38 (+1.00)

Midday Glance: Biotechnology companies
AP - Mon Nov 17, 1:21PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 102.04 (+1.60), AMGN: 160.54 (+1.40), CELG: 106.47 (+2.11)

Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!
Abba's Aces - at Seeking Alpha - Mon Nov 17, 11:35AM CST

BIIB: 305.10 (+2.68), GILD: 102.04 (+1.60), INCY: 70.05 (+0.35), ALXN: 189.94 (+3.16), CELG: 106.47 (+2.11)

Stock Market News for November 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:10AM CST
Benchmarks finished almost flat on Friday as Eurozone’s soft GDP data offset encouraging economic reports
DHI: 24.52 (+0.03), HAS: 55.99 (-0.38), BIIB: 305.10 (+2.68), VRTX: 111.42 (-0.20), HAL: 49.55 (+0.32), M: 60.99 (-0.62), WMT: 83.73 (+0.16), SLB: 95.69 (+0.06), COG: 33.36 (-0.17), GILD: 102.04 (+1.60), EOG: 96.99 (+0.64), ALXN: 189.94 (+3.16), MRO: 31.86 (+0.04), CSCO: 26.56 (+0.09), BHI: 65.75 (+0.52)

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 109.00 (+0.70), GILD: 102.04 (+1.60), ABBV: 65.69 (+0.65), CELG: 106.47 (+2.11)

3 Stocks the Smartest Investors Are Buying Right Now
Motley Fool Staff - Motley Fool - Mon Nov 17, 6:51AM CST
Stocks have soared to new heights over the last few years. Does this mean there are no longer any good buys out there? According to three of our contributing writers, that's not the case. 1. Broad-market exchange-traded funds ( John Maxfield )...
VOO: 188.15 (+0.72), GILD: 102.04 (+1.60), PFE: 30.55 (+0.23)

Intercept Pharmaceuticals Appoints Lisa Bright as Head of Europe
GlobeNewswire - Mon Nov 17, 5:01AM CST
Intercept Pharmaceuticals (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today the appointment of Lisa Bright as Senior Vice President and Head of Europe, effective November 17, 2014. Ms. Bright will be a member of the Intercept senior management team and will spearhead Intercept's European operations based in London as the company prepares for the first indication approval and launch of obeticholic acid (OCA).
GILD: 102.04 (+1.60), ICPT: 163.16 (+5.06)

Studies: New Oral HCV Drug is Effective but Expensive; CBCD Reviews a Report
PRWeb - Sun Nov 16, 11:03PM CST
"Infected with the hepatitis C virus (HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
GILD: 102.04 (+1.60)

'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 327.39 (+4.34), TSRO: 30.76 (+0.77), XBI: 171.76 (+3.38), IBB: 293.91 (+5.07), CELG: 106.47 (+2.11), GILD: 102.03 (+1.59), GLD: 114.96 (+0.91), MCD: 96.13 (+0.16), SLV: 15.55 (+0.05), GDX: 19.85 (+0.46), TWTR: 40.58 (+0.11), AAPL: 114.34 (+0.35), BABA: 111.91 (-2.34)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading